Chan Zuckerberg Biohub Network

What Chan Zuckerberg Biohub Network does

Chan Zuckerberg Biohub Network is a non-profit research organization operating as part of the Chan Zuckerberg Initiative, the philanthropy of Priscilla Chan and Mark Zuckerberg. Founded in 2021 and headquartered in San Francisco, the organization states its mission as curing or preventing all disease by building technology that enables scientists to study how cells operate, organize, and work as part of systems. It functions as a large-scale scientific platform combining frontier AI with frontier biology, deploying compute, AI research and engineering, and laboratory infrastructure at a scale intended to overcome the data-sparsity barriers that have historically limited AI applications in biology.

The organization's core product portfolio centers on ESM (Evolutionary Scale Modeling), an open discovery engine described as a world model of protein biology that can generate, test, and refine billions of possible protein designs grounded in deep biological understanding. Supporting capabilities include a multi-dimensional imaging platform with proprietary laser phase plate technology capable of near-atomic detail of molecular machinery inside cells, frontier AI models trained on the organization's own biological datasets to predict cellular behavior, and three applied research programs targeting inflammation decoding, immune cell reprogramming for age-related disease, and rare disease research acceleration. High-throughput data generation engines produce the structured biological datasets that feed and refine the AI models.

Biohub does not operate on a commercial revenue model. As a philanthropic research entity, its outputs include open research findings, freely available AI models distributed through biohub.ai, and partnerships with investigators worldwide via its investigator program. Its only 'customer segment' is defined horizontally as the global community of scientific researchers, engineers, and AI/ML experts who use the organization's tools. Leadership includes Joe DeRisi as President. Headcount is reported in the 251–500 range, and the organization maintains an active careers presence to recruit across scientific and engineering disciplines.

Name

Chan Zuckerberg Biohub Network

Legal name

Biohub

Website

https://czbiohub.org

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

251–500 employees

Short description

Chan Zuckerberg Biohub Network is a non-profit research organization building AI-powered biology tools — including the ESM protein discovery engine, multi-dimensional imaging with laser phase plate technology, and engineered immune cells — to help scientists worldwide understand and cure disease. Funded by the Chan Zuckerberg Initiative.

Ownership category

akta.pro rank

Product category

AI-Powered Biomedical Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

Keywords

• AI-powered biology
• Biomedical research
• Protein modeling
• Multi-dimensional imaging
• Computational biology

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Distribution channels1 record

Marketing channels5 records

Core offering

Chan Zuckerberg Biohub Network is a nonprofit research organization that builds AI-powered biology technology, including frontier AI models, high-throughput data generation engines, and multi-dimensional imaging tools, to help scientists study cellular behavior and disease mechanisms. Its core offering is the ESM (Evolutionary Scale Modeling) open discovery engine that makes protein biology computable, alongside research programs in inflammation, immune cell reprogramming, and rare disease.

Product overview

Chan Zuckerberg Biohub Network is a research organization building AI-powered biology technology to cure or prevent all disease. Their core product portfolio centers on ESM (Evolutionary Scale Modeling) — an open discovery engine that makes protein biology computable and generates billions of possible protein designs. Supporting this are multi-dimensional imaging tools (including laser phase plate technology for near-atomic detail), frontier AI models trained on biological datasets, and specialized research programs focused on inflammation decoding, immune cell reprogramming, and rare disease research. The organization operates high-throughput data generation engines and discovery platforms that combine frontier AI with frontier biology at unprecedented scale of compute.

Differentiator

Problem solved

Functional benefit

Products and services

• ESM (Evolutionary Scale Modeling) An open discovery engine that makes biology computable, generating billions of possible protein designs that can be tested and refined based on deep biological understanding. Built with frontier AI as a world model of protein biology.
• Multi-dimensional Imaging Platform Imaging tools that capture life across scales from single proteins to whole organisms, revealing how cells function, communicate, and assemble into living systems. Includes laser phase plate technology for near-atomic detail imaging.
• AI Models for Biology Frontier artificial intelligence models trained on vast and unique biological datasets to predict how human cells behave and how they can change. Used by scientists to craft new theories, design powerful experiments, and make breakthrough discoveries about human health and disease.
• Inflammation Research Tools Tools enabling precise molecular-level measurements of inflammation within human tissues in real time, supporting development of proactive early interventions when inflammation first flares in the body.
• Immune Cell Reprogramming AI models and engineered cells that harness immune cells to detect and treat early signs of age-related diseases like cancer, Alzheimer's, and Parkinson's by delivering targeted treatment only when and where it is needed.
• Rare Disease Research Program Data, infrastructure, and partnerships that accelerate translation from basic discovery to patient benefit for rare diseases.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Atomic AI: Atomic AI applies foundation models to RNA structure and biology, intersecting Biohub's multimodal AI-biology and protein world-model strategy in the structural-biology sub-domain.
• EvolutionaryScale: EvolutionaryScale was founded around the ESM protein language model technology, directly out of Biohub's AI research. It represents the commercial spinout tangentially competing with Biohub's own ESM in protein design and generative biology.

Direct peers

• Arc Institute: Arc Institute is a nonprofit biomedical research organization co-located with Stanford that also pursues large-scale, high-risk science with patient philanthropic funding. As a structurally identical peer, it is the most comparable non-profit research model to Biohub.
• Genesis Therapeutics: Genesis uses graph neural networks and AI to design protein-targeting therapeutics; both companies focus heavily on AI-driven protein design and drug discovery, making it a close technology-overlap peer to Biohub's ESM work.
• Insitro: Insitro uses ML on large-scale, high-throughput biological data (including imaging and omics) to predict drug behavior and patient response. Its data-generation-plus-AI model closely mirrors Biohub's high-throughput data engines and AI biology approach.
• Generate Biomedicines: Generate is a generative biology company building AI models to design novel protein therapeutics across a wide range of diseases, sharing Biohub's ESM-driven "make biology computable" thesis. It is a primary private-sector analog to Biohub's ESM protein world model.
• Schrödinger, Inc. Schrödinger applies physics-based computational chemistry and ML to molecule and protein design for drug discovery. It is a long-standing incumbent serving the same scientific customer base Biohub targets with its AI-biology platform.
• Recursion Pharmaceuticals: Recursion combines high-throughput wet-lab biology with AI/ML models and image-based phenotypic data to drive drug discovery. Both Recursion and Biohub center their thesis on pairing frontier AI with proprietary biological data generation, making them highly comparable despite Biohub's non-profit structure.

Others

• Flagship Pioneering: Flagship Pioneering creates and funds platform biotechnology companies at the intersection of biology and computation. As the parent of multiple AI-bio platform companies, it is an adjacent ecosystem enabler to Biohub's open-science platform.

Broad incumbents

• Isomorphic Labs: Alphabet-owned Isomorphic Labs applies DeepMind's protein and chemistry AI to drug discovery. Its commercial reach and DeepMind resources make it the most capable established counterpart to Biohub's AI-protein-biology research platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/czbiohub
• YouTubeyoutube.com/@officialbiohub
• Facebookfacebook.com/czbiohub
• LinkedInlinkedin.com/company/cz-biohub
• Instagraminstagram.com/biohub

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chan Zuckerberg Biohub Network